- Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium

Journal of American Medical Association (JAMA) Papers Related to SARS-CoV-2 Antibody Testing

- Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

The Lancet Papers Related to SARS-CoV-2 Antibody Testing

-  Antibody dynamics to SARS-CoV-2 in Asymptomatic and Mild COVID-19 patients
- SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months
-  Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan–[negative] implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2
- Comparative performance of five commercially available serologic assays to detect antibodies to SARS-coV-2 and identify individuals with high neutralizing titers. 

MedRxiv Preprint Papers Related to SARS-CoV-2 Antibody Testing

- Journal of American Medical Association (JAMA)
- The Lancet
- MedRxiv preprint

University of Michigan - Ann Arbor

University of South Florida

Northwestern University

In order to determine prior infection with SARS-CoV-2, the virus that causes COVID-19, some testing locations have offered testing for SARS-CoV-2 antibodies. A positive test result indicates you may have antibodies from an infection with the virus that causes COVID-19, or from infection with a related virus from the same family of viruses.

It is not yet known if having antibodies to the virus that causes COVID-19 can protect someone from getting infected again or, if they do, how long this protection might last.

SARS-CoV-2 Antibody Testing

- Geneva, Switzerland
- Belgium
- Wanzhou. China
- Spain
- Germany
- New York, USA

Learn Before

Related

Learn After